Modelling shows semaglutide reduces BMI in adolescents, indicating its efficacy and safety for this age group.
PK/PD and safety modelling indicated 1.7 mg semaglutide provides comparable exposure, tolerability and meaningful BMI reduction in adolescents versus adults and versus 2.4 mg. These results supported approval of 1.7 mg for adolescents ≥ 12 years in the November 2024 Wegovy label, obviating a dedicated adolescent 1.7-mg placebo trial.
No takes yet. Share an insight, caveat, or question.
Strathe et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: